In this discussion with an EU-based KOL, we dive into the IBD disease landscape. The KOL discuss the current treatment approach, while highlighting the unmet needs and challenges in the indications. He also speaks on the future of IBD with the novel treatment options waiting in the pipeline, while also hinting at the expected success of these agents. 

This interview was conducted on 9 July 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.